KIORA PHARMACEUTICALS, INC. Payments of Stock Issuance Costs
KIORA PHARMACEUTICALS, INC. (KPRX) reported Payments of Stock Issuance Costs of $71.70 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-08-07
- KIORA PHARMACEUTICALS, INC. payments of stock issuance costs for the quarter ending 2025-12-31 was $0.00.
- KIORA PHARMACEUTICALS, INC. payments of stock issuance costs for the quarter ending 2025-09-30 was $0.00.
- KIORA PHARMACEUTICALS, INC. payments of stock issuance costs for the quarter ending 2024-12-31 was $0.00.
- KIORA PHARMACEUTICALS, INC. payments of stock issuance costs for the quarter ending 2024-09-30 was $0.00.
- KIORA PHARMACEUTICALS, INC. payments of stock issuance costs for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- KIORA PHARMACEUTICALS, INC. payments of stock issuance costs for fiscal 2024 was $1.19M.
- KIORA PHARMACEUTICALS, INC. payments of stock issuance costs for fiscal 2021 was $1.00M, a 101.49% increase from fiscal 2020.
- KIORA PHARMACEUTICALS, INC. payments of stock issuance costs for fiscal 2020 was $498.69K, a 413.68% increase from fiscal 2019.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $71.70K 10-Q · filed 2026-08-07 | |||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $0.00 derived: sum of 2 quarters · filed 2026-03-25 | $0.00 10-K · filed 2026-03-25 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $0.00 10-Q · filed 2025-11-07 | ||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-07 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $0.00 derived: sum of 2 quarters · filed 2026-03-25 | -$1.14K derived: sum of 3 quarters · filed 2026-03-25 | $1.19M 10-K · filed 2026-03-25 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$1.14K derived: sum of 2 quarters · filed 2025-11-07 | $1.19M 10-Q · filed 2025-11-07 | |
| 2024-06-30 | -$1.14K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $1.19M 10-Q · filed 2025-08-08 | ||
| 2024-03-31 | $1.19M 10-Q · filed 2024-05-10 | |||
| 2023-03-31 | $84.28K 10-Q · filed 2024-05-10 | |||
| 2021-12-31 | $1.00M 10-K/A · filed 2022-07-07 | |||
| 2020-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-07-07 | $498.69K 10-K/A · filed 2022-07-07 | ||
| 2020-09-30 | $498.69K 10-Q · filed 2020-11-09 | |||
| 2019-12-31 | $85.52K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $97.08K 10-K · filed 2021-03-25 | ||
| 2019-09-30 | $11.56K 10-Q · filed 2020-11-09 | |||
| 2019-03-31 | $0.00 10-Q · filed 2019-05-08 | |||
| 2018-09-30 | $0.00 10-Q · filed 2019-11-07 | |||
| 2018-03-31 | $40.39K 10-Q · filed 2019-05-08 | $40.39K derived: sum of 2 quarters · filed 2019-05-08 | $40.39K derived: sum of 3 quarters · filed 2019-05-08 | $1.28M derived: sum of 4 quarters · filed 2019-05-08 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-02 | $0.00 derived: sum of 2 quarters · filed 2018-03-02 | $1.23M derived: sum of 3 quarters · filed 2018-03-02 | $1.33M 10-K · filed 2018-03-02 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | $1.23M derived: sum of 2 quarters · filed 2017-11-14 | $1.33M 10-Q · filed 2017-11-14 | $1.33M derived: sum of 4 quarters · filed 2018-05-11 |
| 2017-06-30 | $1.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04 | $1.33M 10-Q · filed 2017-08-04 | $1.33M derived: sum of 3 quarters · filed 2018-05-11 | $1.33M derived: sum of 4 quarters · filed 2018-05-11 |
| 2017-03-31 | $98.32K 10-Q · filed 2018-05-11 | $98.32K derived: sum of 2 quarters · filed 2018-05-11 | $98.32K derived: sum of 3 quarters · filed 2018-05-11 | $422.13K derived: sum of 4 quarters · filed 2018-05-11 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-02 | $0.00 derived: sum of 2 quarters · filed 2018-03-02 | $323.81K derived: sum of 3 quarters · filed 2018-03-02 | $323.81K 10-K · filed 2018-03-02 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | $323.81K derived: sum of 2 quarters · filed 2017-11-14 | $323.81K 10-Q · filed 2017-11-14 | |
| 2016-06-30 | $323.81K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04 | $323.81K 10-Q · filed 2017-08-04 | ||
| 2016-03-31 | $0.00 10-Q · filed 2017-05-05 | |||
| 2015-06-30 | $68.52K 10-Q · filed 2015-08-12 | |||
| 2014-12-31 | $1.15M 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |